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Table 1. Grading evidence and recommendations
Evidence Notes
High quality Further research is very unlikely to change our confidence in the estimate of effect A
Moderate quality Further research is likely to have an important impact on our confidence in the estimate of effect and 
may change the estimate
B
Low quality Further research is very likely to have an important impact on our confidence in the estimate of effect 
and is likely to change the estimate. Any change of estimate is uncertain
C
Recommendation Notes
Strong Factors influencing the strength of the recommendation included the quality of the evidence, presumed 
patient-important outcomes, and cost
1
Weak Variability in preferences and values, or more uncertainty. Recommendation is made with less 
certainty, higher cost or resource consumption
2
INTRODUCTION
Liver cirrhosis (LC) is a disease with a high rate of 
prevalence and one of the most common causes of mortality 
in the Republic of Korea (hereafter "Korea"). In Korea, 
the main etiologies of LC have been found to be chronic 
hepatitis B (CHB), alcohol, and chronic hepatitis C (CHC). 
In patients with complications such as ascites, variceal 
bleeding, and encephalopathy, the 5-year survival rates were 
32%, 21%, and 40%, respectively, reflecting the poor 
prognosis of patients with LC. Consequently, a clinical practice 
guideline appropriate for the medical milieu of Korea is 
important for both patients and clinicians. 
In 2005, the Korean Association for the Study of the Liver 
established a guideline for the treatment of LC that is now 
widely used. However, it is currently necessary to revise and 
update the clinical practice guideline based on new evidence 
over the past 6 years regarding the diagnosis, treatment, and 
prevention of LC. Therefore, the Korean Association for the 
Study of the Liver undertook a revision and update of 
the clinical practice guideline co-organized by the Liver 
Cirrhosis Clinical Research Center. This guideline was based 
on an interdisciplinary (hepatology, radiology, pathology, and 
preventive medicine) approach. A panel of experts selected 
by the Korean Association for the Study of the Liver and 
Liver Cirrhosis Clinical Research Center met several times 
to discuss and write this guideline during 2005-2011. This 
guideline was written in light of published studies retrieved 
from MEDLINE, EMBASE, and Cochrane Library. The 
panel aimed to address 5 subjects: diagnosis of LC, anti- 
fibrotic therapy for LC, variceal bleeding, ascites, and hepatic 
encephalopathy. 
The evidence and recommendations made in this 
guideline have been graded according to the GRADE 
(Grading of Recommendations Assessment Development 
and Evaluation) system. The strength of evidence has 
been classified into 3 levels: A (high-quality evidence), B 
(moderate-quality evidence), and C (low-quality evidence). 
The strength of recommendation has been classified into 2 
categories: strong and weak (Table 1). Where there was no 
clear evidence, the recommendations were based on the 
consensus expert opinion(s) in literature and that of the 
writing committee.
1. Diagnosis of LC
LC is a pathologically defined disease, and is clinically 
classified as compensated and decompensated LC. Decom-
pensated LC includes cases with ascites, variceal bleeding, 
hepatic encephalopathy, or jaundice. Image studies for 
diagnosing LC are CT, abdominal ultrasound, and MRI. 
Typical findings of these images are nodular liver surface, 
splenomegaly, and the presence of intra-abdominal collateral 
vessels, which mean increasing portal venous pressure. 
Although there are not established criteria for the diagnosis 
of compensated LC, imaging studies may be helpful for the 
diagnosis of LC b    y integrating laboratory findings such as 
albumin, bilirubin, or prothrombin time and platelet values.
1-1. Diagnostic approach-patient history, physical 
examination, and laboratory tests
When dealing with patients with LC, evaluation of the 
cause, severity, and stage is the first step. In patients with 
chronic liver disease, history taking (drug use, blood transfusion, 
or alcohol use), physical examination (jaundice, ascites, Ki Tae Suk, et al. Revision and update on clinical practice guideline for liver cirrhosis  3
Recommendations
1. What test is needed for the diagnosis of LC in patients with 
chronic liver disease?
- Find evidence for LC by history taking and physical 
examination. (A1)
- In patients with chronic liver disease, to find LC, the 
following tests are recommended and the findings in 
parentheses should be checked. (A1)
(1) Complete blood count with platelet count 
(thrombocytopenia)
(2) Liver function test (hypoalbuminemia)
(3) Prolonged prothrombin time
(4) Imaging studies (nodularity of liver surface and 
findings of LC)
(5) Endoscopy (presence of varices)
- The cause of LC should be examined including hepatitis 
B virus and hepatitis C virus tests. (A1)
- The severity of LC could be assessed by Child-Pugh 
classification with score. (B1)
2. Which findings are compatible with the diagnosis of LC in 
the imaging studies?
- For the diagnosis of LC, compatible findings of imaging 
studies (abdominal ultrasound, CT, and MRI) are 
morphologic changes (nodularity of liver surface, atrophy 
of the right lobe, hypertrophy of the left and caudate lobe, 
expansion of the periportal space, and intrahepatic 
nodule), ascites, and presence of portal hypertension 
(collateral vessel or splenomegaly). (B1)
spider angioma, hepatomegaly, or splenomegaly), and symptom 
such as fatigue from hepatitis should be assessed. In patients 
with LC, a whole blood test including platelet count, liver 
function test (albumin, aspartate aminotransferase, alanine 
aminotransferase, alkaline phosphatase, and gamma glutamyl 
transpeptidase), prothrombin time, abdominal ultrasound, 
abdominal CT, and endoscopy should be carried out to 
confirm the presence or absence of cirrhosis. In addition, 
laboratory tests for hepatitis B or C virus infection are 
needed for the evaluation of its cause. Generally, the Child- 
Pugh score is used to assess the severity of LC. In clinical 
practice for the diagnosis of LC, findings of portal hyper-
tension such as ascites, hepatic encephalopathy, or varices, 
imaging findings, and laboratory findings are common 
diagnostic tools. Recently, it was found that nodularity of 
the liver surface, a platelet count of less than 100,000/mm
3, 
albumin less than 3.5 g/dL, and an international normalized 
ratio of 1.3 or more are related to the presence of LC. 
Presence of one condition of these findings showed a 
specificity of 90.42% and a sensitivity of 61.11%.
1
1-2. Imaging modalities for the diagnosis of LC
Abdominal ultrasound is safe and less expensive, and it 
can be easily used as a screening test for the diagnosis of LC. 
Abdominal ultrasound confirms the size of the liver, 
echogenicity of the liver parenchyme, morphological 
changes of the liver, ascites, and thrombus of the portal vein. 
Typical ultrasound finding of LC is a coarse echo pattern by 
fibrosis and regeneration. This finding ranges from mild 
coarsening to visible nodules. The accuracy of CT in 
diagnosing LC is 66-95%.
2-6 The most important CT finding 
for the diagnosis of LC is nodularity caused by regenerative 
nodules, fibrosis scars, and lobar non-uniform atrophy and 
hypertrophy. Nodularity of the liver surface showed a 
specificity of 95%.
2-4,7 Additionally, other radiologic findings 
such as splenomegaly, blunt angle, morphological changes 
(nodularity of liver surface, atrophy of right lobe, hypertrophy 
of left and caudate lobe, expansion of periportal space, and 
intrahepatic nodule), velocity of portal flow, shape of 
hepatic vein waveform (Doppler test),
2,4,8 and caudate 
lobe/right lobe ratio (CT or MRI) are useful indices.
9 If the 
caudate lobe/right lobe ratio is above 0.65, it can indicate 
LC, and its sensitivity, specificity, and accuracy reach 84%, 
100%, and 94%, respectively.
10
1-3. Pathological diagnosis of liver cirrhosis
The gold standard for confirming the diagnosis of LC is 
liver biopsy, but it is invasive and susceptible to a sampling 
error and inter-observer discrepancy. Therefore, liver biopsy 
has not been widely used in clinical practice. Liver biopsy 
can be carried out selectively for evaluating activity of the 
underlying disease and fibrosis. Particularly, when cirrhosis 
is diagnosed by clinical findings and imaging studies, but 
not compatible with laboratory data, a liver biopsy is 
especially helpful for diagnosing LC.
11
1-4. Others
The serum markers for liver fibrosis directly or indirectly 
reflect extracellular matrix metabolism. However, their 
clinical utility in the diagnosis of LC has not been verified.
12 
FibroScan has been introduced to measure liver elasticity 
noninvasively and is an objective diagnostic tool for the 
diagnosis of LC. However, there is no exact guideline on 
how to apply it clinically, and there is some variation in its 
diagnostic accuracy for the diagnosis of LC. Therefore, the 
practical use of FibroScan is limited.4  The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
3. When should liver biopsy be performed in patients with 
chronic liver disease for the diagnosis of LC?
- Liver biopsy should be selectively performed to detect the 
cause of LC and assess the disease activity and fibrosis. 
Liver biopsy is necessary on patients in whom the 
diagnosis remains unclear from the conventional test (B1)
2. Anti-fibrotic therapy for LC
LC is a pathological condition of liver fibrosis generated 
by continuous scar formation and recovery due to chronic 
liver injury, eventually leading to the development of 
regenerative nodules around the fibrotic scar.
13 If liver 
injury is chronically repeated, damaged liver cells cannot 
regenerate and instead migrate to the extracellular matrix 
such as collagen.
14 The mechanism of liver fibrosis is 
variable, depending on causes such as alcohol, hepatitis 
virus, or bile acids. Hepatic stellate cells, which are located 
in the space of Disse, play a major role in liver fibrosis.
14 
Histological changes associated with LC have long been 
believed to be irreversible. However, in patients receiving 
antiviral therapy for CHB, liver fibrosis has been observed 
to be significantly improved.
15 Similarly, the primary approach 
to treating LC is treatment of the underlying disease. The 
second approach in the treatment of LC is anti-fibrotic 
therapy that targets the liver fibrosis-generating mechanism 
irrespective of the cause of LC. In order to develop effective 
treatments for liver fibrosis, the molecular pathogenesis 
and treatment of liver fibrosis have been exhaustively 
investigated over the last 2 decades. Subsequently, a number 
of substances or drugs with anti-fibrotic effects in animal 
experiments have been found; however, most of these have 
not been verified for use in human beings. 
2-1. Chronic hepatitis B
Antiviral therapy that regulates inflammation via the 
inhibition of viral proliferation is recommended for improving 
liver fibrosis.
15-21 There were no significant differences in 
the degree of improvement in fibrosis according to antiviral 
drugs.
22-24 As liver fibrosis progresses, the rate of improvement 
by antiviral treatment increases.
18,25 Therefore, in patients 
with advanced liver fibrosis, antiviral treatment is needed in 
the case with viral proliferation. In patients with LC due to 
CHB, antiviral therapy with a sufficient treatment period 
can be recommended to reduce liver fibrosis from virus 
proliferation. However, in the case of drug-resistant viral 
infection, the benefits of antiviral treatment are reduced.
19,22,26
The extent of liver fibrosis was reduced by 49% when 
treated with interferon α or peginterferon α.
20 In patients 
with HBeAg-positive CHB, hepatic fibrosis improved in 
39% of patients after initial treatment with entecavir, whereas 
in HBeAg-negative CHB, improvement was observed in 
36% of patients.
23,27 With 1-year tenofovir treatment, inflam-
mation improved without aggravation in 74% of HBeAg- 
positive CHB patients and in 71% of HBeAg-negative CHB 
patients.
21,24,28
2-2. Chronic hepatitis C
Interferon treatment for CHC reduces the hepatic necrotic 
inflammatory reaction; particularly, in patients with a 
sustained virological response, the reductions in serum 
hepatitis C virus RNA and intrahepatic necrotic inflammatory 
reactions are correlated.
29 In particular, antiviral treatment 
should be actively considered for patients presenting with 
genotype 2 or 3 and a Child-Pugh score <7. In patients 
with a Child-Pugh score of 7-9, antiviral treatment can be 
considered with careful attention to hepatic dysfunction.
30-34 
2-3. Alcohol 
Abstinence is the most important treatment of alcoholic 
liver disease.
35 Abstinence not only improves fibrosis in 
hepatic tissue but also reduces portal pressure and inhibits 
progression to LC. Ultimately, the survival rate of patients in 
all stages of alcoholic liver disease increases following 
abstinence, with improvements being observed in up to 66% 
of patients.
35 Sustained drinking increases the risk of 
variceal bleeding by portal hypertension and is closely 
related with mortality.
In severe alcoholic hepatitis, steroid and pentoxifylline 
therapy have been recommended by several studies. However, 
the effect of these drugs on fibrosis has not been confirmed; 
therefore, these medications are not recommended in the 
treatment of fibrosis as anti-fibrotic therapy. 
2-4. Nonalcoholic fatty liver
Treatment of nonalcoholic fatty liver comprises improving 
insulin resistance, removing risk factors of metabolic 
syndrome, lifestyle modifications, drug therapy, and operative 
treatment.
36-52 Weight loss appears to help in liver steatosis 
as well as relieves hepatic inflammation and fibrosis.
36-39 
Therefore, the first choice of therapy in nonalcoholic fatty 
liver disease is weight loss through diet therapy and lifestyle Ki Tae Suk, et al. Revision and update on clinical practice guideline for liver cirrhosis  5
Recommendations
1. What is anti-fibrotic therapy according to the causes of LC?
- In patients with LC, it is recommended that the cause of 
disease should be treated to improve liver fibrosis. (A1)
- In patients with LC due to CHB, antiviral therapy with a 
sufficient treatment period can be recommended to reduce 
liver fibrosis from virus proliferation. (B1)
- In patients with LC due to CHC, antiviral therapy with a 
combination of peginterferon and ribavirin can be 
recommended, if the normal range of liver function with 
viral proliferation. In addition, monitoring for side effects 
is needed. (B1)
- In patients with alcoholic LC, strict abstinence is 
recommended to prevent worsening of disease. (A1)
- In patients with nonalcoholic fatty liver disease, losing 
weight, diet therapy, and exercise can be recommended. 
(B1)
- In patients with primary biliary cirrhosis, ursodeoxycholic 
acid is recommended with a dose of 13-15 mg/kg/day. 
(A1)
Recommendations
1. What is the role of endoscopy in patients with LC?
- It is recommended that all patients undergo endoscopy 
when they are first diagnosed with LC in order to 
evaluate the presence of esophageal varix and the risk of 
bleeding. (A1)
- Esophageal varices are classified into small (F1) and large 
(F2 and F3). Also, red color sign should be checked during
endoscopy. (B1)
- For patients with compensated LC should be considered 
for endoscopy every 2 to 3 years, and patients with 
decompensated LC every 1 to 2 years in order to evaluate 
the occurrence and progression of varices. (B1)
- Patients with compensated LC with small varices not 
using nonselective beta-blocker, should be considered for 
endoscopy every 2 years to evaluate the progression of 
varices. (B1)
- The frequency of endoscopy can be adjusted according to 
the cause and progression of LC.
modifications, with more than 7% weight loss being the 
recommended target.
39 For nonalcoholic fatty liver disease, 
clinical trials using multiple drugs have currently being 
attempted. However, data regarding its effectiveness, safety, 
and dosing period remain limited.
40 
2-5. Primary biliary cirrhosis
Ursodeoxycholic acid has been proven to improve 
primary biliary cirrhosis and is the only drug recognized for 
its treatment.
53-56 Ursodeoxycholic acid reduces serum 
bilirubin levels, which is an important prognostic factor, and 
delays the progression and deterioration of fibrosis
55,56 
13-15 mg/kg/day is the most effective dose in terms of 
biological effect and cost-effectiveness. Improvements of 
liver function tests appear within 6-9 months of therapy in 
more than 90% of patients.
57 Ursodeoxycholic acid treatment 
is not known to improve fatigue, itching, bone diseases, or 
autoimmune reactions associated with primary biliary 
cirrhosis.
57
3. Variceal bleeding
Esophageal variceal bleeding is found in approximately 
40% of patients with Child-Pugh A class LC, and in 
approximately 80% of patients with Child-Pugh C class 
LC.
58 The risk of variceal bleeding depends on the size of 
varices, red color sign, and the Child-Pugh classification. 
Variceal bleeding due to portal hypertension can be prevented 
when the value of hepatic venous pressure gradient is lower 
than 12 mmHg or when it is decreased to lower than 20% of 
the baseline measurement.
59 
3-1. Diagnosis
It is recommended that all patients undergo endoscopy 
when they are first diagnosed with LC in order to evaluate 
the presence of esophageal varix and the risk of bleeding.
60 
Esophageal varices are classified based on the diameter of 
varices and their morphology as follows: varices with the 
findings of larger than 5 mm
61 or F2-F3 (beaded varices - 
crystalled varices) are defined as large and varices with the 
findings of smaller than 5 mm or F1 (straight varices) are 
defined as small.
62 Treatment to prevent esophageal variceal 
bleeding should be performed when large varices are 
present. For patients with compensated LC should be 
considered for endoscopy every 2 to 3 years, and patients 
with decompensated LC every 1 to 2 years in order to 
evaluate the occurrence and progression of varix.
63 Patients 
with compensated LC with small varices not using 
nonselective beta-blocker, should be considered for 
endoscopy every 2 years to evaluate the progression of 
varix.
3-2. Acute esophageal variceal bleeding
3-2-1. Definition and diagnosis
Acute variceal bleeding is defined as hematemesis within 
last 24 hours of presentation, and/or ongoing melena, with 
the last melenic stool within last 24 hours before the hospital 
visit in a known or suspected case of portal hypertension. 6  The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
Table 2. Drugs for acute esophageal variceal bleeding
Type Effect Dose, usage, duration
Terlipressin Side effect (cardiac ischemia)
Improve survival rate
Effect on hepatorenal syndrome
Inject 2 mg at first and inject 1-2 mg every 4-6 hours 
until control bleeding or use for 3 days
Somatostatin Side effects 
(intestinal vessel constriction, vomiting, or hyperglycemia)
Do not improve survival rate
Somatostatin: IV 250 μg at first and 250 μg/hour for 
2-3 days
Antibiotics Reduce bacterial infection
Improve survival rate
Ceftriaxone: IV 1g/day for 5-7 days
Norfloxacin: PO 400 mg twice a day for 5-7 days
Recommendations
2. How should acute variceal bleeding be treated? 
- It is recommended that patients with acute variceal 
bleeding initially be administered vasoconstrictor and 
antibiotic treatment. (A1)
- Endoscopic treatment is recommended for patients with 
acute variceal bleeding. (A1)
- TIPS can be recommended if drugs and endoscopic therapy 
have failed or endoscopic treatment is impossible. (B1)
Endoscopy is the most definite diagnostic method for 
identifying acute esophageal variceal bleeding. Variceal 
bleeding can be diagnosed as follows: direct visualization of 
blood issuing from esophageal varices, presence of signs of 
recent bleeds on varices such as white nipple sign or 
overlying clot, or presence of blood in the stomach in the 
absence of another source of bleeding.
64
3-2-2. Treatment 
The first line of therapy includes vasoconstrictors such as 
terlipressin and somatostatin.
65 Antibiotics are recommended 
for patients admitted in the hospital.
66 Antibiotic therapy is 
recommended for 5-7 days to prevent sepsis and rebleeding 
following endoscopy (Table 2).
67
Medication and endoscopic therapy are recommended in 
patients with acute variceal bleeding for the first time.
68 If 
active bleeding is present, banding of the culprit vessel or 
that just below the ooze should be performed endoscopically. 
After ligation of the active bleeding site, even in the absence 
of active bleeding, banding should be performed starting 
from just above the gastro-esophageal junction (5-10 mm) 
in a sequential manner up to 5 cm. Endoscopic injection 
sclerotherapy is recommended if endoscopic variceal ligation 
is technically impossible or has failed.
Balloon tamponade can be used as a rescue therapy if 
active variceal bleeding cannot be controlled. Transjugular 
intrahepatic portosystemic shunt (TIPS) is recommended 
if medication and endoscopic therapy have failed or if 
endoscopic therapy is impossible.
3-3. Prevention
3-3-1. Prevention of first bleeding in patients without 
esophageal varices
Nonselective beta-blockers are not recommended in 
patients without esophageal varices.
69,70
3-3-2. Prevention of first bleeding in patients with small 
esophageal varices 
Nonselective beta-blockers do not lower the incidence 
of bleeding in patients with small esophageal varices.
71 
However, patients with a high risk of bleeding (Child-Pugh 
class B/C or endoscopic red color sign), are considered for 
nonselective beta-blocker therapy.
70 The dose of nonselec-
tive beta-blockers is adjusted for a reduction in the resting 
heart rate by 25%, to 55 beats/minute, or until the occurrence 
of side effects. In Koreans, the mean adjusted dose of 
propranolol is 160 mg/day.
72,73
3-3-3. Prevention of first bleeding in patients with large 
esophageal varices
In large esophageal varices, endoscopic variceal ligation 
(EVL) and nonselective beta-blockers are effective in 
preventing the first bleeding occurrence.
74,75 In patients with 
large varices (F2 or F3), which have never been observed to 
bleed, nonselective beta-blockers or EVL is recommended. 
Repeated EVL is recommended until the disappearance 
of esophageal varices.
76 Low doses of carvedilol have been 
shown to lower the frequency of variceal bleeding Ki Tae Suk, et al. Revision and update on clinical practice guideline for liver cirrhosis  7
Recommendations
3. How can a first variceal bleeding be prevented in patients 
with LC?
- In patients without varices, a nonselective beta-blockers 
are not recommended for the purpose of preventing the 
formation of varix and first bleeding of esophageal varix. 
(B1)
- Nonselective beta-blockers should be considered for 
patients with small varices which have never bled but 
have a high risk of bleeding (Child-Pugh class B/C or red 
color sign on endoscopy). (B1) 
- In patients with large varices (F2 or F3) in which bleeding 
has never been observed, nonselective beta-blockers or 
EVL are recommended. (A1)
4. How should nonselective beta-blockers be administered to 
patients with LC?
- Nonselective beta-blockers are adjusted at the dose of 
reduction in resting heart rate by 25% or 55 beats/minute, 
or until the side effects occur. (B1)
Recommendations
5. How to prevent recurrence of variceal bleeding? 
- Patients who experience acute variceal bleeding need 
treatment to prevent rebleeding. (A1)
- EVL alone or in combination with nonselective 
beta-blockers should be considered for the prevention of 
rebleeding. (B1)
- TIPS should be considered as a rescue therapy in Child- 
Pugh A/B patients in whom other therapies have failed. 
(B1)
- Liver transplantation should be considered for patients 
who meet indications for liver transplantation. (B1)
with lesser side effects as compared with EVL. However, 
additional research is needed before they can be routinely 
used.
66,77 Combination therapy with EVL and nonselective 
beta-blockers for the prevention of first bleeding has shown 
no differences as compared with monotherapy.
78
3-4. Prevention of variceal rebleeding
3-4-1. Definition and diagnosis
Variceal rebleeding is defined as bleeding after 5 days of 
recovery from acute variceal bleeding.
70 It is diagnosed 
similar to acute variceal bleeding.
3-4-2. Prevention 
Nonselective beta-blockers alone or combination therapy 
with isosorbide mononitrate are known to be effective in the 
prevention of rebleeding.
79 EVL shows better outcomes than 
endoscopic injection sclerotherapy in endoscopic therapy 
for prevention of rebleeding.
80 Rebleeding has been reported 
in 32% of patients after EVL. Combination therapy of EVL 
and nonselective beta-blockers has been shown to have 
better outcomes than EVL alone.
81,82 
TIPS shows a significantly low rebleeding rate as compared 
with endoscopic therapy. However, it shows a significantly 
high incidence of hepatic encephalopathy. TIPS is not 
recommended as a first-line therapy for esophageal variceal 
bleeding and is recommended only as a rescue therapy when 
combination therapy fails.
83 Liver transplantation should be 
considered for patients who meet indications for liver 
transplantation.
84,85
If the hepatic venous pressure gradient is reduced to less 
than 12 mmHg or to more than 20% reduction in baseline 
levels by medical therapy, the incidence rate of rebleeding is 
low (10%).
86 In such cases, further endoscopic therapy may 
not be required.
3-5. Gastric varices
3-5-1. Definition and diagnosis
Gastric varices are enlarged submucosal veins of the 
stomach that cause critical upper gastrointestinal bleeding. 
Gastric varices occur in approximately 20% of patients with 
portal hypertension, and the bleeding rate in 2 years is 
known to be 25%.
87 Diagnosis is performed by endoscopy. 
Endoscopic ultrasound can also be helpful.
88
3-5-2. Classification
Gastroesophageal varices are classified depending on 
whether esophageal varices are extended along lesser 
curvature (gastroesophageal varices, GOV1) or gastric 
fundus (GOV2). Gastric varices alone are classified as 
varices located in the fundus (isolated gastric varices, IGV1) 
and any other regions, i.e., stomach or duodenum (IGV2).
87
3-5-3. Treatment and prevention
EVL is recommended for the treatment of GOV1. 
Endoscopic variceal obturation (EVO) can be an alter-
native.
89-93 EVO involves the injection of tissue adhesives 
such as N-butyl-2-cyanoacrylate (histoacryl
Ⓡ) into the 
varices via endoscopy and can be recommended in treating 
GOV2 and IGV.
91,94-96 Endoscopic injection sclerotherapy is 
not recommended in treating GOV2 or IGV1 because of its 
low rate of hemostasis, high rate of rebleeding, and other 
complications.
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Recommendations
6. How should gastric variceal bleeding be treated?
- In gastric variceal bleeding, EVL or EVO are considered 
for GOV1 accompanying esophageal varices extended 
along the lesser curvature. (B1)
- EVO is preferable in patients with GOV2 or IGV1. If 
endoscopic treatment is not possible, TIPS can be used. If 
gastric varix is accompanied with gastrorenal shunt, 
balloon-occluded retrograde transvenous obliteration can 
be considered. (B1)
- Surgery such as distal splenorenal shunt or vascular shunt 
should be considered for patients (Child-Pugh A/B) and 
liver transplantation for patients (Child-Pugh B/C) who 
are not eligible for endoscopic treatment.
Recommendations
7. How should portal hypertensive gastropathy be treated?
- If chronic bleeding due to portal hypertensive gastropathy 
presents, nonselective beta-blockers can be used. (B1)
Recommendations
1. How should ascites of LC be diagnosed?
- Paracentesis should be performed when Grade 2 or 3 
ascites occurs, when there is clinical suspicion of 
infection, or when there are complications of LC such as 
encephalopathy or kidney dysfunction. (A1)
- When the initial paracentesis is performed, a total cell 
count and differential, albumin, and total protein tests 
should be performed. A culture of ascitic fluid in blood 
culture bottles at the bedside is recommended. (A1)
- If serum-ascites albumin gradient is greater than or equal 
to 1.1 g/dL, it indicates ascites by portal hypertension. (B1)
TIPS can be performed.
101,102 If a gastrorenal shunt is 
present, balloon-occluded retrograde transvenous obliteration 
can be performed.
103-106 Surgery, such as distal splenorenal 
shunting or vascular shunting, can be attempted if endoscopic 
treatment is not possible in case of Child-Pugh A/B patients, 
while liver transplantation is considered in the case of 
Child-Pugh B/C patients.
107
Empirical use of nonselective beta-blockers, balloon- 
occluded retrograde transvenous obliteration, and EVO can 
prevent first gastric variceal bleeding, while EVO, TIPS, 
and balloon-occluded retrograde transvenous obliteration 
are considered to prevent gastric variceal rebleeding.
70,108
3-6. Portal hypertensive gastropathy
3-6-1. Diagnosis 
Portal hypertensive gastropathy is diagnosed when gastric 
mucosal changes of snake-skin appearance (or mosaic 
pattern) are found on endoscopy in patients with portal 
hypertension.
109 When gastric mucosal changes alone are 
found, this is diagnosed as a mild form. When red or dark 
brown viscous changes with changes in gastric mucosa are 
found, it is considered severe.
72 Severe portal hypertensive 
gastropathy causes more chronic bleeding than does the mild 
form.
110
3-6-2. Treatment 
In chronic bleeding due to portal hypertensive gastropathy, 
the goal of treatment is lowering the portal pressure with 
nonselective beta-blockers. In addition, iron supplementation 
is recommended.
111 Despite these treatments, if repeated 
transfusions are needed for the treatment of chronic anemia, 
TIPS can be considered.
112
4. Ascites
Ascites is the most common complication in LC, 
occurring in 60% of the patients with compensated LC 
within 10 years.
113 Ascites appears in 2/3 of the patients who 
required admission due to LC,
114 and 60% of the patients 
requiring paracentesis is because of LC.
115 
4-1. Diagnosis
Abdominal ultrasound can diagnose ascites with only 100 
mL.
116 Ascites is classified by the amount of fluid as follows: 
Grade 1 is diagnosed through imaging study, Grade 2 
through inspection and physical examination, Grade 3 based 
on marked abdominal expansion. Paracentesis is the most 
useful and simple diagnostic tool in Grade 2 or 3 ascites. 
Furthermore, paracentesis should be performed in cirrhotic 
patients with fever, abdominal pain, bleeding, encephalopathy, 
hypotension, or kidney dysfunction to assess for spontaneous 
bacterial peritonitis (SBP), since 10-27% of the patients with 
ascites have SBP.
117 The main purpose of paracentesis is to 
discriminate the cause of ascites. Therefore, screening tests 
should include total cell count and differential, albumin, and 
total protein. Blood cell count is the most useful test for 
diagnosing SBP. For differential diagnosis of ascites, a 
serum-ascites albumin gradient can be calculated. If the 
serum-ascites albumin gradient is is greater than of equal to 
1.1 g/dL, ascites is ascribed to portal hypertension with an 
accuracy of 97%.Ki Tae Suk, et al. Revision and update on clinical practice guideline for liver cirrhosis  9
Table 3. Treatment of ascites depending on the grade
Grade 1, mild Grade 2, moderate Grade 3, severe
Low-salt diet ●○○
Diuretic ● ○
Large volume paracentesis ●
Grade 1, a small amount of ascites detected in the ultrasound test; Grade 2, ascites of the amount which distends abdomen 
symmetrically; Grade 3, ascites of the large volume which distends abdomen; ●, major treatment; ○, recommended.
4-2. Treatment
Although controversial,
118 a low salt diet is considered 
effective for controlling ascites and shortening hospitalization. 
Less than 5 g/day of salt (sodium for 2 g, 88 mEq) is 
recommended. When plasma sodium is lower than 120-125 
mEq/L, water intake should be restricted to 1-1.5 L/day.
119
4-2-1. Medications
If severe ascites is present, diuretic therapy should be used 
for negative sodium balance.
120,121  Secondary hyperaldo-
steronism in patients with LC induces reabsorption of 
sodium and water in the distal renal tubule and collecting 
tubule, consequently causing hypokalemia. Aldosterone 
antagonists inhibit this mechanism, and hence is mainly 
used for controlling ascites in patients with LC. Spirono-
lactone has a long half-life but has a slow onset of action, 
and therefore requires 3-4 days to achieve a stable 
concentration. It is initiated at a dose of 50-100 mg/day, with 
a maximum dose of 400 mg/day. Side effects include 
hyperkalemia, gynecomastia, mastalgia, hyposexuality, and 
erectile dysfunction.
122 
Loop diuretics operate by blocking Na-K-2Cl receptors in 
the thick ascending limb of Henle’s loop. They are mostly 
used along with aldosterone antagonists in patients with LC. 
Hypokalemia may occur as a side effect, but via such 
mechanism, hyperkalemia caused by the aldosterone anta-
gonist can be corrected. The starting dose is 20-40 mg/day, 
with the maximum dose being 160 mg/day. Monotherapy 
with loop diuretics is less effective than aldosterone anta-
gonist monotherapy. Spironolactone monotherapy can be 
used initially on patients with ascites.
123 Combination 
therapy of an aldosterone antagonist and a loop diuretic is 
recommended at first in a ratio of 100:40, which stabilizes 
plasma potassium levels. Combination therapy shows a 
faster effect in controlling ascites and lowers the possibility 
of hyperkalemia as compared to aldosterone monotherapy.
124
When peripheral edema is present, the rate of weight loss 
should be no greater than 1 kg/day. For patients without 
edema, 0.5 kg/day of weight loss is ideal.
120,125 If there is no 
weight loss even with 5 g/day of salt intake, the diet and 
diuretic dose should be evaluated by examining the amount 
of urinary sodium excretion per day.
120,126 Patients with low 
salt intake should not excrete more than 78 mEq of urinal 
sodium in 24 hours. In such patients, if urinary sodium 
excretion is more than 78 mEq, low salt intake is judged not 
to be followed. When the excretion is less than 78 mEq, the 
diuretic is considered to be inadequate and the dose needs 
to be increased. Spot urine Na/K ratio of more than 1 repre-
sents 24 hours urine sodium excretion more than 78 mEq.
127
It is important to check the weight loss, vital sign, changes 
in consciousness level, and the level of plasma sodium, 
potassium, and creatinine during diuretic administration. 
When plasma sodium is more than 126 mEq/L, diuretics can 
be used without the restriction of water intake. However, 
when plasma sodium is less than 125 mEq/L, the physician 
should consider cessation or reduction in the dose of the 
diuretic and restriction of water intake. If plasma sodium is 
less than 120 mEq/L, the diuretic and water intake should be 
stopped and a plasma expander such as albumin should be 
administered. If plasma sodium is less than 125 mEq/L with 
kidney dysfunction, the diuretic should be stopped and a 
plasma expander should be administered.
128 If plasma 
potassium is less than 3.5 mEq/L, the dose of loop diuretic 
should be reduced or stopped. If plasma potassium is more 
than 5.5 mEq/L, the dose of aldosterone antagonist should 
be reduced. And if plasma potassium is more than 6.0 
mEq/L, the aldosterone antagonist should be ceased.
120
4-2-2. Therapeutic paracentesis (reference to intractable 
ascites section)
Therapeutic paracentesis is an effective treatment for 
tension-type ascites, because it relieves the symptoms more 
quickly than diuretics and shortens hospitalization 
(Table 3).
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Recommendations
2. How should ascites of LC be treated?
- Patients with cirrhotic ascites should be advised to take in 
less than 5 g of salt a day. (B1)
- When the serum sodium is normal, restriction of water 
intake is not necessary. (B1)
- Bed rest is not recommended for the treatment of ascites. 
(B1)
- The first-choice diuretic for patients with cirrhotic ascites 
is aldosterone antagonist. (A1) Loop diuretics can be used 
along with aldosterone antagonist. (B1) Spironolactone 
can be used with a starting dose of 50-100 mg/day up to 
400 mg/day. To increase the diuretic effects and maintain 
a normal serum potassium level, 20-40 mg of furosemide 
should be used with spironolactone (40:100) beginning at 
the initial stage. 
- When peripheral edema is present, the rate of weight loss 
should be recommended up to 1 kg/day. For patients 
without edema, 0.5 kg/day of weight loss should be 
recommended. (A1)
- In cases of severe hyponatremia, kidney dysfunction, 
encephalopathy, or severe muscle spasms, diuretics should 
be stopped. (B1)
- In cases of hypokalemia, loop diuretic should be reduced 
or stopped, and if hyperkalemia occurs, the dose of 
aldosterone antagonist should be adjusted. (B1)
- Therapeutic large volume paracentesis is recommended as 
the first-line treatment for tension-type ascites. (A1)
Table 4. Definition and diagnosis of refractory ascites
206
Diuretic resistant ascites Being not responsive to sodium limit and diuretic, ascites is not controlled, and recurs early 
Diuretic intractable ascites Since sufficient amount of diuretic cannot be given for its complication, ascites is not controlled, and 
recurs early 
Required conditions 
Treatment period For over a week, give sufficient amount of diuretics (spironolactone 400 mg/day and furosemide 160 
mg/day) and restriction of sodium intake to 5 g/day
Treatment response Body weight loss is less than 800 g during 4 days, and the amount of urine sodium excretion is less 
than the amount taken 
Early recurrence of ascite Within 4 weeks after paracentesis, grade 2 or 3 ascites recurs
Complications Hepatic encephalopathy
Renal dysfunction: after giving diuretics, serum creatinine goes up over 100%, and exceeds 2.0 mg/dL 
Hyponatremia: serum sodium reduces by over 10 mEq/L, and goes down below 125 mEq/L
Hypokalemia or hyperkalemia: serum potassium goes down below 3 mEq/L, or goes up beyond 6 mEq/L 
4-3. Refractory ascites and hyponatremia
4-3-1. Refractory ascites
Refractory ascites
130 is defined as fluid overload that (1) is 
not controlled despite restriction of sodium intake and the 
maximum dose of diuretics, and (2) recurs rapidly after 
paracentesis. There are 2 types of refractory ascites-diuretic 
resistant and diuretic intractable (Table 4).
Large-volume paracentesis is not considered for every 
patient as a first-line treatment. It can be selectively 
performed in occasions in which the patient has difficulties 
eating or breathing because of abdominal distension. After 
relieving the symptoms by paracentesis, the maintenance 
treatment should be administered. In the case of large- 
volume paracentesis over 5 L, an infusion of 8-10 g of 
albumin per L is recommended. In the case of paracentesis 
less than 5 L, although the occurrence of circulatory 
dysfunction is not frequent, an infusion of volume expander 
can be considered. Albumin can also be used for this 
purpose.
125,131 Medications such as midodrine,
132 norad-
renaline,
133 or terlipressin
134 can be used. Compared with 
repetitive paracenteses, TIPS is an effective method to 
prevent the recurrence of ascites and the occurrence 
hepatorenal syndrome. However, hepatic encephalopathy 
occurs in 30-50% of cases after TIPS. As 21% of the patients 
with refractory ascites die within 6 months and the median 
survival period is also less than 1 year, they should be 
considered for liver transplantation.
135 
4-3-2. Hyponatremia 
The diagnostic criterion for hyponatremia is less than 130 
mEq/L.
119 A hypervolemic state can be corrected to normal 
by a negative water balance. Eventually, dilutional 
hyponatremia can be improved.
136 Restriction of water 
intake can prevent a decrease in the serum sodium level.
125 
Hypertonic sodium injection can worsen ascites and 
edema.
137 Plasma expanders can be useful in the treatment of 
hyponatremia.
138 Vaptan,
139 a selective vasopressin 2 receptor 
antagonist of arginine vasopressin, leads to the excretion of Ki Tae Suk, et al. Revision and update on clinical practice guideline for liver cirrhosis  11
Recommendations
3. How should intractable ascites be treated?
- Repetitive large volume paracentesis is recommended in 
patients with refractory ascites. (A1)
- In the case of large volume paracentesis, 8-10 g/L (albumin/
ascites) is recommended for the prevention of postparacentesis 
circulation dysfunction. (A1)
- TIPS can be used for the treatment of refractory ascites. (B1)
- Because of poor prognosis, liver transplantation is 
recommended in patients with refractory ascites. (A1) 
- If the serum sodium concentration is less than 120-125 
mEq/L, restriction of fluid intake to 1-1.5 L/day is recom-
mended. (A1)
- Albumin or vaptan can be used in severe dilutional hypo-
natremia (<125 mEq/L). (B2)
Table 5. New International Ascites Club's diagnostic criteria of hepatorenal syndrome
1) Cirrhosis with ascites
2) Serum creatinine >133 mmol/L (1.5 mg/dL)
3) No improvement of serum creatinine (decrease to a level of 133 mmol/L) after at least 2 days with diuretic withdrawal and volume
expansion with albumin; the recommended dose of albumin is 1 g/kg of body weight per day up to a maximum of 100 g/day
4) Absence of shock
5) No current or recent treatment with nephrotoxic drugs
6) Absence of parenchymal kidney disease as indicated by proteinuria >500 mg/day, microhematuria (>50 red blood cells/high-power
field), and/or abnormal renal ultrasound.
solute-free water. This agent can be used in the treatment of 
hyponatremia caused by inappropriate antidiuretic hormone 
secretion, heart failure, or liver cirrhosis. In the United 
States and Europe, tolvaptan and conivaptan are approved 
for the treatment of severe hyponatremia (<125 mEq/L).
4-4. Hepatorenal syndrome
4-4-1. Definition and diagnosis
Renal failure in LC occurs in 2 forms. First, type 1 
hepatorenal syndrome is a rapid progressive acute renal 
dysfunction which occurs due to the strong contraction of 
the renal vasculature. Type 2 hepatorenal syndrome is a 
relatively slow process with a rather moderate renal 
dysfunction. The most important mechanism involved in the 
occurrence of hepatorenal syndrome is decreased effective 
blood volume due to the dilation of the splanchnic and 
peripheral circulation. This situation activates the sympathetic 
nervous system as well as the renin-angiotensin system and 
causes functional renal disorder.
140-142
In 1994, the International Ascites Club announced the 
diagnostic criteria for hepatorenal syndrome; in 2007, 
they revised these criteria to providing clearer diagnostic 
methods and including infectious diseases (Table 5).
130,143
4-4-2. Treatment 
Dilatation of splanchnic artery and decrease in effective 
arterial blood volume arethe primary mechanisms of 
hepatorenal syndrome. The effect of albumin monotherapy 
is not sufficient in this situation.
144,145 Vasoconstrictors have 
been used in the treatment of the hepatorenal syndrome, and 
combination therapy with vasoconstrictors and albumin is 
effective in hepatorenal syndrome. The combination therapy 
of terlipressin and albumin improves renal function in 
60-75% of the patients.
144,146-152 Maintenance therapy is 
possible up to 15 days or until the serum creatinine 
levels decrease (<1.5 mg/dL). Further, long-term usage 
(approximately 2 months) can be considered as a bridging 
therapy prior to liver transplantation.
153,154 The combination 
therapy of noradrenaline and albumin can also improve 
renal function in hepatorenal syndrome.
155,156 Combination 
therapy of midodrine and octreotide or triple therapy of 
midodrine, octreotide, and albumin also meaningfully improve 
renal function in patients with hepatorenal syndrome.
157-160
After administration of terlipressin, hepatic venous 
pressure gradient is known to decrease while the renal blood 
flow increases.
161,162 Therefore, it can also be used for 
treatment in patients with secondary renal insufficiency due 
to variceal bleeding.
147,163,164
Although TIPS
157,165,166 reduces the serum creatinine 
levels in most patients with hepatorenal syndrome, the effect 
is slower than the combined use of terlipressin and albumin. 
In a group that used molecular adsorbent recirculating 
system
167 in the treatment of hepatorenal syndrome, 
laboratory findings (serum creatinine, bilirubin, and 
prothrombin time) and 30-days survival rate were improved 
compared to the group that underwent intermittent dialysis 
and drug therapy. Continuous arterio-venous hemofiltration 
and continuous veno-venous hemofiltration can be considered 
to minimize the changes in blood pressure.
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Recommendations
4. How should hepatorenal syndrome be treated?
- In type 1 hepatorenal syndrome, combination therapy of 
terlipressin and albumin can improve renal function. (A1)
- In type 1 hepatorenal syndrome, combination therapy of 
midodrine, octreotide, and albumin can be considered. 
(B2)
- The best treatment for type 1 hepatorenal syndrome is 
liver transplantation. (A1)
- In high risk patients who have ascites accompanied by 
SBP, the use of albumin can decrease the incidence of 
hepatorenal syndrome. (A1)
Recommendations
5. How should SBP be diagnosed and treated? 
- If SBP is suspected and the result of paracentesis show a 
PMN of more than 250/mm
3, empirical antibiotic therapy 
should be started immediately without results of ascitic 
fluid culture. (A1)
- Third-generation cephalosporine is recommended as an 
initial antibiotic. (A1)
- The patient with symptoms or signs of infection should 
receive empirical antibiotics while awaiting of ascitic fluid 
culture even if the number of PMN is less than 250/mm
3. 
(A1)
- If the secondary bactrieal peritonitisis suspected, an 
imaging study such as a CT should be performed (A1), 
and additional examinations such as those for total 
protein, LDH, glucose, or gram staining can be performed. 
(B1)
- If the patient has a history of SBP, gastrointestinal bleeding, 
or protein in ascites less than 1.5 g/dL, although there is no
gastrointestinal bleeding, prophylactic antibiotics should 
be considered because the chance of SBP is high. (B1)
4-4-3. Prevention 
Hepatorenal syndrome can be prevented by inhibiting the 
decrease of plasma volume. Diuretics and lactulose should 
be used carefully to prevent excessive fluid loss.
132,133,170,171 
In patients with SBP, the use of albumin and antibiotics 
reduce the incidence of hepatorenal syndrome.
172,173 The use 
of oral norfloxacin has been shown to reduce the occurrence 
of hepatorenal syndrome and increase 3-month survival 
rates in patients with low serum protein (<1.5 g/dL) or renal 
insufficiency (creatinine ≥1.2 mg/dL, or blood urea nitrogen 
≥25 mg/dL, or serum Na ≤130 mEq/L).
174 Administration of 
pentoxifylline improved survival rates as compared to 
corticosteroids in severe acute alcoholic hepatitis patients 
(Maddrey’s discriminant factor ≥32).
175-177
4-5. Spontaneous bacterial peritonitis
4-5-1. Definition and diagnosis
SBP is bacterial infection of ascites, without an evident 
intra-abdominal, surgically treatable source of infection. It 
occurs in 10-30% of the patients with cirrhotic ascites and 
recurs in 70% of the patients within 1 year even if 
treated.
126,178
SBP can be diagnosed in patients with findings of ascitic 
polymorphonuclear leukocyte (PMN) ≥250/mm
3and bacteria 
in the ascitic culture without an evident intra-abdominal 
infection. If ascites fluid contains red blood cells, PMN is 
calculated by subtracting 1/mm
3 per red blood cell 750 
/mm
3. Culture-negative neutrocytic ascites is a condition 
where ascitic PMN ≥250/mm
3 but no cultured bacteria are 
observed. These patients show a clinical course mostly 
similar to patients with SBP. Empiric antibiotics treatment is 
recommended. Monomicrobial non-neutrocytic bacterascites 
is a condition with ascitic PMN <250/mm
3, but cultured 
single-strain bacteria being observed.
4-5-2. Treatment 
Administration of third generation cephalosporin is 
recommended. Cefotaxime is recommended at a dose of 2 g 
every 6-8 hours by intravenous injection. Subsequently, 
selective antibiotic therapy based on the result of ascites 
culture should be administered for 5-10 days.
179 Treatment 
duration varies according to the symptoms and/or results of 
antibiotic sensitivity. Albumin during the treatment of SBP, 
especially in patients with renal dysfunction, can be 
helpful.
173
4-5-3. Prevention
If a patient presentsacute gastrointestinal bleeding, 
administration of norfloxacin at a dose of 400 mg twice daily 
for 7 days orally or ceftriaxone at a dose of 1 g daily for 
7 days intravenously is effective in preventing SBP. In 
patients with a concentration of protein in ascites fluid less 
than 1.5 g/dL or bilirubin in plasma is more than 2.5 mg/dL, 
administration of norfloxacin at a dose of 400 mg daily for 
longer than 6 months orally is effective in prolonging the 
survival.
5. Hepatic encephalopathy
5-1. Definition 
Hepatic encephalopathy is a neuropsychiatric syndrome 
that follows liver dysfunction. Patients with hepatic 
encephalopathy can show various neurological illnesses Ki Tae Suk, et al. Revision and update on clinical practice guideline for liver cirrhosis  13
Table 6. Classification of hepatic encephalopathy
180
HE type Nomenclature Subcategory Subdivisions
A Encephalopathy associated with acute liver failure
B Encephalopathy associated with portal-systemic bypass and no intrinsic 
hepatocellular disease
C Encepahlopathy associated with cirrhosis and portal hypertension/or 
systemic shunts
Episodic HE Precipitated
Spontaneous
Recurrent
Persistent HE Mild
Severe
Treatment-dependent
Minimal HE
HE, hepatic encephalopathy.
Table 7. West-Haven criteria for hepatic encephalopathy
183
Grade Consciousness Intellect and behavior Neurologic findings
0 Normal Normal Normal examination; if impaired psychomotor 
testing then MHE
1 Mild lack of awareness Shortened attention span; impaired 
addition or subtraction
Mild asterixis or tremor
2 Lethargic Disoriented; inappropriate behavior Obvious asterixis; slurred speech
3 Somnolent but arousable Gross disorientation; bizarre behavior Muscular rigidity and clonus; hyperreflexia
4 Coma Coma Decerebrate posturing
MHE, minimal hepatic encephalopathy.
such as cognition and orientation disorders. Hepatic 
encephalopathy is classified into 3 groups according to the 
causative liver disease (Table 6).
180,181
5-2. Diagnosis 
Hepatic encephalopathy is generally accompanied by 
advanced liver disease; therefore, muscle weakness, jaundice, 
ascites, palmar erythema, edema, spider telangiectasias, and 
fetor hepaticus can be noted on physical examination. 
Clinicians should check for gastrointestinal hemorrhage, 
uremia, use of anti-psychotics or diuretics, protein hyper-
ingestion, infection, constipation, dehydration, electrolyte 
imbalance, etc.
182 Common symptoms include concentration 
disorders, sleep disorders, and movement disorders, including 
lethargy or coma. The severity of hepatic encephalopathy 
can be evaluated using the West Haven criteria (Table 7).
183
Venous levels of ammonia are not helpful because they 
are not proportional to the severity of hepatic encephalopathy 
and some patients with sever hepatic encephalopathy have 
normal venous ammonia levels.
184 
Brain MRI is considered better than brain CT in the 
diagnosis of brain edema accompanying hepatic failure, but 
this is not true for hepatic encephalopathy. Brain CT is 
useful when differentiating between organic causes of 
neuropsychiatric disorders such as intracranial hemorrhage.
185
5-3. Treatment 
The goal of treatment is to prevent secondary damage 
caused by decreased consciousness, normalize the patient’s 
state of consciousness, prevent recurrence, and to improve 
the prognosis and quality of life by eliminating the social 
and economic restrictions caused by hepatic encephalopathy. 
The precipitating factor can be identified in more than 80% 
of patients with hepatic encephalopathy.
182 The currently 
known precipitating factors of hepatic encephalopathy 
and the corresponding tests and treatments are shown in 
Table 8.
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Table 8. Precipitating factors, tests, and treatment of hepatic encephalopathy
186
Precipitating factor Tests Treatment
Gastrointestinal bleeding Endoscopy, complete blood count, digital rectal 
examination, stool blood test
Transfusion, bleeding treatment, vasoactive drugs
Infection Complete blood count, chest x-ray, urine analysis, 
culture, diagnostic paracentesis
Broad-spectrum antibiotics
Constipation History taking, abdomen x-ray Enema or drug therapy
Protein intake History taking Limiting protein intake
Dehydration Skin elasticity, blood pressure, pulse rate, blood 
urea nitrogen, creatinine
Stop diuretics or reduction, fluid therapy
Renal dysfunction Blood urea nitrogen, creatinine Stop diuretics or reduction, albumin, fluid therapy
Hyponatremia Serum sodium concentration Restriction water consumption, diuretics dose 
adjustment or stop
Hypokalemia Serum potassium concentration Diuretics dose adjustment or stop
Benzodiazepines History taking Stop drug, flumazenil
Acute liver dysfunction Liver function test Conservative treatment
5-3-1. Medications
The primary treatment of hepatic encephalopathy is 
nonabsorbable disaccharides such as lactulose (β-galactosido- 
fructose) or lactitiol (β-galctoside sorbitol). These 
treatments lead to the recovery of 70-90% of patients with 
hepatic encephalopathy. Although nonabsorbable disaccha-
rides have been reported to have no significant effect on 
hepatic encephalopathy,
187 randomized controlled studies 
have indicated a positive effect of lactulose in the treatment 
and prevention of hepatic encephalopathy.
188,189 Enema with 
nonabsorbable disaccharides can be used until the cons-
ciousness is recovered. After consciousness is restored, 
nonabsorbable disaccharides (15-45 mL, orally 2-4 times/day) 
should be recommended for loose stool defecation 2-3 times 
a day. 
Antibiotics such as neomycin, metronidazole, and 
rifaximin that are not absorbed by the intestine, affect 
urea-producing bacteria and reduce the generation of 
ammonia, thereby improving hepatic encephalopathy. 
Neomycin and metronidazole are not recommended as 
atreatment of hepatic encephalopathy because of their side 
effects such as intestinal malabsorption, nephrotoxicity, and 
ototoxicity for neomycin and peripheral neuropathy for 
metronidazole.
190 Rifaximin maintains high levels of 
concentration in the intestine because it is not absorbed by 
the intestine and remains in an active form until it is 
excreted. It has a broad antimicrobial activity on aerobic and 
anaerobic gram-positive and gram-negative bacteria. It has 
been proven effective and safe in hepatic encephalopathy,
191-193 
and recently has been focused upon as a first-line treatment 
for hepatic encephalopathy with a maximum dose of 1,200 
mg/day.
Ornithine and aspartate are important substrates used to 
metabolize ammonia to urea and glutamine. L-ornithine- 
L-aspartate (LOLA) can therefore be administered to 
patients with hepatic encephalopathy for reducing blood 
ammonia levels, with subsequent improvements in hepatic 
encephalopathy. LOLA is available in oral and injection 
forms, both of which are available in Korea currently.
5-3-2. Liver transplantation
Liver transplantation is indicated in patients with severe 
hepatic encephalopathy, who do not respond to the above 
treatments. Patient with acute liver failure who shows hepatic 
encephalopathy are also considered for liver transplantation 
because of the poor prognosis.
194
5-3-3. Prevention of relapse
Because the recurrence rate of hepatic encephalopathy is 
50-70%,
189,195,196 therapy for the prevention of recurrence 
should be considered. Lactulose
189 or rifaximin
196 have been 
used for the prevention of recurrence. 
5-4. Minimal hepatic encephalopathy
5-4-1. Definition and diagnosis
Minimal hepatic encephalopathy is a mild form of hepatic 
encephalopathy that is defined as a cognitive dysfunction 
presenting a abnormal psychometric tests without clinical Ki Tae Suk, et al. Revision and update on clinical practice guideline for liver cirrhosis  15
Recommendations
1. What are the precipitating factors of hepatic 
encephalopathy?
- Precipitating factors of hepatic encephalopathy are 
gastrointestinal bleeding, infection, constipation, excessive 
intake of protein, dehydration, renal function disorder, 
electrolyte imbalance, psychoactive medication, and acute 
hepatic injury. (A1)
2. How should hepatic encephalopathy be treated?
- Nonabsorbent disaccharides (ex. lactulose, lactitol) (A1) 
and rifaximin (B1) are recommended for treating patients 
with hepatic encephalopathy. Nonabsorbable disaccharides 
can be used to adjust the bowel movement-loose stool 
(2-3 times/day), and rifaximin 1,200 mg should be given 
orally in 2-3 divided doses for 1-3 weeks.
- A lactulose enema is recommended in severe hepatic 
encephalopathy (West Haven grade ≥III). (A1)
- LOLA can be used in patients with hepatic 
encephalopathy, and LOLA of 20 g can be injected daily 
for 1-2 weeks or LOLA of 6 g can be given orally 3 times
per day for 1-2 weeks. (B2)
- Flumazenil can be used in patients with hepatic 
encephalopathy caused by benzodiazepine for the 
improvement of consciousness. (B2)
- In patients who do not respond to treatment or acute liver 
injury with hepatic encephalopathy, liver transplantation is 
recommended. (A1)
- In patients with a history of hepatic encephalopathy, 
nonabsorbable disaccharide can be used until patients have 
loose stools 2-3 times a day (A1), or 600 mg of rifaximin 
can be used twice a day (B1). 
3. How protein be supplied to patients with hepatic encephal-
opathy?
- Protein intake should be restricted in patients with initial 
hepatic encephalopathy, and gradually can be increased 
according to the patient’s condition. (B1)
- Oral branched-chain amino acids can be used as a protein 
source in case of worsening or recurrence of hepatic 
encephalopathy due to as a consequence of high protein 
intake. (B2)
4. Is it necessary to examine and treat minimal hepatic 
encephalopathy for patients with LC?
- In patients with LC, if there are any symptoms of low 
cognitive function, tests and treatment for minimal hepatic 
encephalopathy can be considered. (B1)
symptoms.
180 Overall, 22-74% of patients with non-fulminant 
hepatic encephalopathy have minimal hepatic encephalo-
pathy,
197 and its frequency is proportional to patient age and 
severity of liver disease.
197  It is impossible to diagnose 
minimal hepatic encephalopathy on clinical examination 
alone. Only mild disturbances in cognitive and psychomotor 
functions can be observed. Patients with minimal hepatic 
encephalopathy exhibit disability in most functional 
behaviors such as social connection, alertness, emotional 
behavior, sleep, work, and leisure.
188,198
Mini-Mental State Examination can be useful in differen-
tiating West Haven criteria 0 and stage 1-2, and if the score is 
23 or lower, it suggests that the patient has overt hepatic 
encephalopathy causing a cognitive disorder and is not 
a primary target for psychometric tests.
199 Since there are 
still no decisive diagnostic tests, psychometric hepatic 
encephalopathy score battery is recommended as a standard 
method consisting of number connection test-A, number 
connection test-B, line drawing test, serial dotting test, and 
digit symbol test, and its benefits have been proven in 
studies from Spain, Germany, India, and Korea.
181,200-202
5-4-2. Treatment 
Cognition and health-related quality of life improve 
significantly in the treatment group compared to placebo 
group.
188 It has been reported that microviral agents (e.g., 
probiotics, synbiotics, etc.) improve minimal encephalopathy 
by changing intestinal normal flora and suppressing the 
production of ammonia.
203 Even though reports are 
displayed that LOLA
204 and acetyl L-carnitine
205 improved 
minimal encephalopathy, there is no evidence regarding its 
effectiveness.
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